Change in Alcohol Use Based on Self-Report and a Quantitative Biomarker, Phosphatidylethanol, in People With HIV.
Alcohol consumption
HIV infection
Phosphatidylethanolamine
Journal
AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
accepted:
11
08
2021
pubmed:
21
9
2021
medline:
16
2
2022
entrez:
20
9
2021
Statut:
ppublish
Résumé
The timeline followback (TLFB) takes more resources to collect than the Alcohol Use Disorder Identification Test (AUDIT-C). We assessed agreement of TLFB and AUDIT-C with the biomarker phosphatidylethanol (PEth) and compared changes in TLFB and PEth among persons with HIV (PWH) using secondary data from randomized trials. We calculated operating characteristics and agreement between TLFB (> 1 and > 2 average drinks/day), AUDIT-C ≥ 4 and PEth ≥ 20 among 275 men with HIV. Median age was 57 years, 80% were African-American; and 17% white. Sixty-eight percent had PEth ≥ 20, 46% reported > 2 average drinks/day on TLFB, 61% reported > 1 average drinks/day on TLFB, and 72% had an AUDIT-C ≥ 4. Relative to PEth, sensitivity for AUDIT-C ≥ 4 was 84% (kappa = 0.36), and for TLFB > 1 average drink/day was 76% (kappa = 0.44). Change in alcohol use appeared greater using TLFB measures than PEth. Strategies to robustly assess alcohol use in PWH may require both self-report and biomarkers.
Identifiants
pubmed: 34542779
doi: 10.1007/s10461-021-03438-y
pii: 10.1007/s10461-021-03438-y
doi:
Substances chimiques
Biomarkers
0
Glycerophospholipids
0
phosphatidylethanol
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
786-794Subventions
Organisme : NIAAA NIH HHS
ID : U10-AA13566
Pays : United States
Organisme : NIAAA NIH HHS
ID : U24-AA020794
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01-AA020790
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01-AA020795
Pays : United States
Organisme : National Institute of Allergy and Infectious Diseases
ID : P30AI050409
Organisme : NIAAA NIH HHS
ID : U10-AA13566
Pays : United States
Organisme : NIAAA NIH HHS
ID : U24-AA020794
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01-AA020790
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01-AA020795
Pays : United States
Informations de copyright
© 2021. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Références
Samet JH, Cheng DM, Libman H, Nunes DP, Alperen JK, Saitz R. Alcohol consumption and HIV disease progression. J Acquir Immune Defic Syndr. 2007;46(2):194.
pubmed: 17667330
pmcid: 2247363
Conigliaro J, Gordon AJ, McGinnis KA, Rabeneck L, Justice AC. How harmful is hazardous alcohol use and abuse in HIV infection: do health care providers know who is at risk? J Acquir Immune Defic Syndr. 2003;33(4):521–5.
pubmed: 12869842
Justice AC, McGinnis KA, Tate JP, Braithwaite RS, Bryant KJ, Cook RL, et al. Risk of mortality and physiologic injury evident with lower alcohol exposure among HIV infected compared with uninfected men. Drug Alcohol Depend. 2016;161:95–103.
pubmed: 26861883
pmcid: 4792710
Williams EC, Hahn JA, Saitz R, Bryant K, Lira MC, Samet JH. Alcohol use and human immunodeficiency virus (HIV) infection: current knowledge, implications, and future directions. Alcohol Clin Exp Res. 2016;40(10):2056–72.
pubmed: 27696523
pmcid: 5119641
McCance-Katz EF, Lum PJ, Beatty G, Gruber VA, Peters M, Rainey PM. Untreated HIV infection is associated with higher blood alcohol levels. J Acquir Immune Defic Syndr. 2012;60(3):282–8.
pubmed: 22495786
pmcid: 3723399
Shuper PA, Joharchi N, Rehm J. Lower blood alcohol concentration among HIV-positive versus HIV-negative individuals following controlled alcohol administration. Alcohol Clin Exp Res. 2018;42(9):1684–92.
pubmed: 29928776
pmcid: 6120761
McGinnis KA, Fiellin DA, Tate JP, Cook RL, Braithwaite RS, Bryant KJ, Edelman EJ, Gordon AJ, Kraemer KL, Maisto SA, Justice AC. Veterans aging cohort study. Number of drinks to “feel a buzz” by HIV status and viral load in men. AIDS Behav. 2016;20(3):504–11.
pubmed: 26936030
pmcid: 4780364
Sobell LC, Sobell MB. Timeline follow-back. In: Litten RZ, Allen JP, editors. Measuring alcohol consumption. Totowa, NJ: Humana Press; 1992.
Sobell LC, Brown J, Leo GI, Sobell MB. The reliability of the Alcohol Timeline Followback when administered by telephone and by computer. Drug Alcohol Depend. 1996;42(1):49–54.
pubmed: 8889403
Bradley KA, Bush KR, Epler AJ, Dobie DJ, Davis TM, Sporleder JL, et al. Two brief alcohol-screening tests from the Alcohol use disorders identification test (AUDIT): validation in a female Veterans Affairs patient population. Arch Intern Med. 2003;163(7):821–9.
pubmed: 12695273
Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res. 2007;31(7):1208–17.
pubmed: 17451397
Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med. 1998;158(16):1789–95.
pubmed: 9738608
Rubinsky AD, Chavez LJ, Berger D, Lapham GT, Hawkins EJ, Williams EC, et al. Utility of routine alcohol screening for monitoring changes in alcohol consumption. Drug Alcohol Depend. 2019;201:155–60.
pubmed: 31229703
pmcid: 7001877
Williams EC, McGinnis KA, Bobb JF, Rubinsky AD, Lapham GT, Skanderson M, et al. Changes in alcohol use associated with changes in HIV disease severity over time: A national longitudinal study in the Veterans Aging Cohort. Drug Alcohol Depend. 2018;189:21–9.
pubmed: 29859388
pmcid: 6344121
Williams EC, McGinnis KA, Edelman EJ, Matson TE, Gordon AJ, Marshall BD, et al. Level of alcohol use associated with HIV care continuum targets in a national US sample of persons living with HIV receiving healthcare. AIDS Behav. 2019;23(1):140–51.
pubmed: 29995206
pmcid: 6344313
Kalichman SC, Amaral CM, White D, Swetsze C, Kalichman MO, Cherry C, et al. Alcohol and adherence to antiretroviral medications: interactive toxicity beliefs among people living with HIV. J Assoc Nurses AIDS Care. 2012;23(6):511–20.
pubmed: 22421097
pmcid: 4271641
Pellowski JA, Kalichman SC, Kalichman MO, Cherry C. Alcohol-antiretroviral therapy interactive toxicity beliefs and daily medication adherence and alcohol use among people living with HIV. AIDS Care. 2016;28(8):963–70.
pubmed: 26964014
pmcid: 4963817
Lapham GT, Rubinsky AD, Williams EC, Hawkins EJ, Grossbard J, Chavez LJ, et al. Decreasing sensitivity of clinical alcohol screening with the AUDIT-C after repeated negative screens in VA clinics. Drug Alcohol Depend. 2014;142:209–15.
pubmed: 25034900
Aradottir S, Asanovska G, Gjerss S, Hansson P, Alling C. Phosphatidylethanol (PEth) concentrations in blood are correlated to reported alcohol intake in alcohol-dependent patients. Alcohol Alcohol. 2006;41(4):431–7.
pubmed: 16624837
Hahn JA, Dobkin LM, Mayanja B, Emenyonu NI, Kigozi IM, Shiboski S, et al. Phosphatidylethanol (PEth) as a biomarker of alcohol consumption in HIV-positive patients in sub-Saharan Africa. Alcohol Clin Exp Res. 2012;36(5):854–62.
pubmed: 22150449
Hahn JA, Anton RF, Javors MA. The formation, elimination, interpretation and future research needs of phosphatidylethanol (PEth) for research studies and clinical practice. Alcohol Clin Exp Res. 2016;40(11):2292.
pubmed: 27716960
pmcid: 5117827
Stewart SH, Koch DG, Willner IR, Anton RF, Reuben A. Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with chronic liver disease. Alcohol Clin Exp Res. 2014;38(6):1706–11.
pubmed: 24848614
pmcid: 4409698
Winkler M, Skopp G, Alt A, Miltner E, Jochum T, Daenhardt C, et al. Comparison of direct and indirect alcohol markers with PEth in blood and urine in alcohol dependent inpatients during detoxication. Int J Legal Med. 2013;127(4):761–8.
pubmed: 23274938
Wurst FM, Thon N, Yegles M, Schrück A, Preuss UW, Weinmann W. Ethanol metabolites: their role in the assessment of alcohol intake. Alcohol Clin Exp Res. 2015;39(11):2060–72.
pubmed: 26344403
Piano MR, Tiwari S, Nevoral L, Phillips SA. Phosphatidylethanol levels are elevated and correlate strongly with AUDIT scores in young adult binge drinkers. Alcohol Alcohol. 2015;50:519–25.
pubmed: 26051989
Stewart SH, Reuben A, Brzezinski WA, Koch DG, Basile J, Randall PK, Miller PM. Preliminary evaluation of phosphatidylethanol and alcohol consumption in patients with liver disease and hypertension. Alcohol Alcohol. 2009;44:464–7.
pubmed: 19535495
pmcid: 2765354
Ulwelling W, Smith K. The PEth blood test in the security environment: what it is; why it is important; and interpretative guidelines. J Forensic Sci. 2018;63(6):1634–40.
pubmed: 30005144
Bajunirwe F, Haberer JE, Boum Y II, Hunt P, Mocello R, Martin JN, et al. Comparison of self-reported alcohol consumption to phosphatidylethanol measurement among HIV-infected patients initiating antiretroviral treatment in southwestern Uganda. PLoS One. 2014;9(12):e113152.
pubmed: 25436894
pmcid: 4249861
Eyawo O, Deng Y, Dziura J, Justice AC, McGinnis K, Tate JP, et al. Validating self-reported unhealthy alcohol use with phosphatidylethanol (PEth) among patients with HIV. Alcohol Clin Exp Res. 2020;44(10):2053–63.
pubmed: 33460225
Littlefield AK, Brown JL, Diclemente RJ, Safonova P, Sales JM, Rose ES, Belyakov N, Rassokhin VV. Phosphatidylethanol (PEth) as a biomarker of alcohol consumption in HIV-infected young Russian Women: comparison to self-report assessments of alcohol use. AIDS Behav. 2017;21:1938–49.
pubmed: 28421353
pmcid: 5642275
Papas RK, Gakinya BN, Mwaniki MM, Keter AK, Lee H, Loxley MP, Klein DA, Sidle JE, Martino S, Baliddawa JB, Schlaudt KL, Maisto SA. Associations between the phosphatidylethanol alcohol biomarker and self-reported alcohol use in a sample of HIV-infected outpatient drinkers inWestern Kenya. Alcohol Clin Exp Res. 2016;40:1779–87.
pubmed: 27426424
pmcid: 4961598
Wang Y, Chen X, Hahn JA, Brumback B, Zhou Z, Miguez MJ, Cook RL. Phosphatidylethanol in comparison to self-reported alcohol consumption among HIV-infected women in a randomized controlled trial of naltrexone for reducing hazardous drinking. Alcohol Clin Exp Res. 2018;42:128–34.
pubmed: 29080351
Hahn JA, Fatch R, Kabami J, Mayanja B, Emenyonu NI, Martin J, et al. Self-report of alcohol use increases when specimens for alcohol biomarkers are collected in persons with HIV in Uganda. J Acquir Immune Defic Syndr. 2012;61(4):e63.
pubmed: 23138732
pmcid: 3495104
Viel G, Boscolo-Berto R, Cecchetto G, Fais P, Nalesso A, Ferrara SD. Phosphatidylethanol in blood as a marker of chronic alcohol use: a systematic review and meta-analysis. Int J Mol Sci. 2012;13(11):14788–812.
pubmed: 23203094
pmcid: 3509610
Walther L, de Bejczy A, Löf E, Hansson T, Andersson A, Guterstam J, et al. Phosphatidylethanol is superior to carbohydrate-deficient transferrin and γ-glutamyltransferase as an alcohol marker and is a reliable estimate of alcohol consumption level. Alcohol Clin Exp Res. 2015;39(11):2200–8.
pubmed: 26503066
Helander A, Hermansson U, Beck O. Dose–response characteristics of the alcohol biomarker phosphatidylethanol (PEth)—a study of outpatients in treatment for reduced drinking. Alcohol Alcohol. 2019;54(6):567–73.
pubmed: 31529064
Richards VL, Sajdeya R, Villalba K, Wang Y, Bryant V, Brumback B, Bryant K, Hahn JA, Cook RL. Secondary analysis of a randomized clinical trial of naltrexone among women living with hiv: Correlations between reductions in self-reported alcohol use and changes in phosphatidylethanol. Alcohol Clin Exp Res. 2021;45(1):174–80.
pubmed: 33190242
Edelman EJ, Maisto SA, Hansen NB, Cutter CJ, Dziura J, Fiellin LE, et al. The Starting Treatment for Ethanol in Primary care Trials (STEP Trials): protocol for three parallel multi-site stepped care effectiveness studies for unhealthy alcohol use in HIV-positive patients. Contemp Clin Trials. 2017;52:80–90.
pubmed: 27876616
Edelman EJ, Maisto SA, Hansen NB, Cutter CJ, Dziura J, Deng Y, et al. Integrated stepped alcohol treatment for patients with HIV and alcohol use disorder: a randomised controlled trial. Lancet HIV. 2019;6(8):e509–17.
pubmed: 31109915
pmcid: 7161741
Jones J, Jones M, Plate C, Lewis D. The detection of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanol in human dried blood spots. Anal Methods. 2011;3:1101–6.
Asiimwe SB, Fatch R, Emenyonu NI, Muyindike WR, Kekibiina A, Santos GM, et al. Comparison of traditional and novel self-report measures to an alcohol biomarker for quantifying alcohol consumption among HIV-infected adults in Sub-Saharan Africa. Alcohol Clin Exp Res. 2015;39(8):1518–27.
pubmed: 26148140
pmcid: 4515166
Schröck A, Wurst FM, Thon N, Weinmann W. Assessing phosphatidylethanol (PEth) levels reflecting different drinking habits in comparison to the alcohol use disorders identification test–C (AUDIT-C). Drug Alcohol Depend. 2017;178:80–6.
pubmed: 28645063
National Institute on Alcohol Abuse, Alcoholism (US). Helping Patients who Drink Too Much: A Clinician's Guide. Updated 2005 Edition. US Department of Health and Human Services, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism; 2007.
Rubinsky AD, Dawson DA, Williams EC, Kivlahan DR, Bradley KA. AUDIT-C scores as a scaled marker of mean daily drinking, alcohol use disorder severity, and probability of alcohol dependence in a U.S. general population sample of drinkers. Alcohol Clin Exp Res. 2013;37(8):1380–90.
pubmed: 23906469